|
|
|
|
|
CUSIP No. 87184Q107
|
|
13G
|
|
Page
4
of 7
|
Item 1(a). Name of Issuer
The name of the issuer to which this filing on Schedule 13G relates is Syros Pharmaceuticals, Inc. (the Issuer).
Item 1(b). Address of Issuers Principal Executive Offices
The principal executive offices of the Issuer are located at 35 Cambridge Park Drive, 4th Floor, Cambridge, Massachusetts 02140.
Item 2(a). Name of Person Filing
This Schedule 13G
is being filed jointly by Bain Capital Life Sciences Fund II, L.P., a Cayman Islands exempted limited partnership (BCLS II), and BCIP Life Sciences Associates, LP, a Delaware limited partnership (BCIPLS and, together with
BCLS II, the Reporting Persons).
Bain Capital Life Sciences Investors, LLC, a Delaware limited liability company (BCLSI), is the
manager of Bain Capital Life Sciences Investors II, LLC, a Cayman Islands limited liability company (BCLSI II), which is the general partner of BCLS II.
Boylston Coinvestors, LLC, a Delaware limited liability company (Boylston), is the general partner of BCIPLS. BCLSI governs the investment
strategy and decision-making process with respect to investments held by BCIPLS.
As a result, BCLSI may be deemed to share voting and dispositive power
with respect to the securities held by the Reporting Persons.
The Reporting Persons have entered into a Joint Filing Agreement, dated February 14,
2022, pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k)(1) promulgated under the Act.
Item 2(b). Address of Principal Business Office or, if None, Residence
The principal business address for each of the Reporting Persons, BCLSI, BCLSI II and Boylston is 200 Clarendon Street, Boston, MA 02116.
Item 2(c). Citizenship
BCLS II and BCLSI II are
organized under the laws of the Cayman Islands. BCIPLS, BCLSI and Boylston are organized under the laws of the State of Delaware.
Item 2(d).
Title of Class of Securities
The class of securities of the Issuer to which this Schedule 13G relates is Common Stock, $0.001 par value per share
(Common Stock).
Item 2(e). CUSIP Number
The CUSIP number of the Common Stock is 84184Q107.